Want to see VKTX full AI Analyst Report?
Top Page
Viking Therapeutics
(NASDAQ:VKTX)
Select Model
Select Model
Rating:52Neutral
Price Target:
$26.00
▼(-23.91% Downside)
Action:Reiterated
Date:10/29/26
The score is held back primarily by weak financial performance (no revenue, escalating losses, and significant cash burn) and a bearish technical setup (price below key moving averages and negative MACD). These are partially offset by a strongly positive earnings call focused on meaningful clinical progress and program advancement, while valuation provides limited signal due to negative earnings and no dividend.
Positive Factors
Clinical Pipeline Progress
Advancing both injectable and oral VK2735 programs into late-stage trials strengthens Viking’s development platform and expands potential product formats. Fully enrolled studies and a new registration program create multiple upcoming clinical milestones that could support future commercialization if results and regulatory reviews are favorable.
Negative Factors
No Commercial Revenue and Widening Losses
Viking has not yet established a commercial revenue stream to offset research and operating costs, leaving its financial outlook dependent on clinical progress and future product approval. Rapidly widening losses increase the amount of capital required before the business can potentially become self-funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical Pipeline Progress
Advancing both injectable and oral VK2735 programs into late-stage trials strengthens Viking’s development platform and expands potential product formats. Fully enrolled studies and a new registration program create multiple upcoming clinical milestones that could support future commercialization if results and regulatory reviews are favorable.
Read all positive factors
Viking Therapeutics (VKTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.22B
Dividend YieldN/A
Average Volume (3M)7.84M
Price to Earnings (P/E)―
Beta (1Y)1.10
Revenue GrowthN/A
EPS Growth-203.77%
CountryUS
Employees65
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.40
Shares Outstanding127,165,250
10 Day Avg. Volume4,608,904
30 Day Avg. Volume7,836,713
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)6.20
Price to Sales (P/S)0.00
P/FCF Ratio-14.22
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-33.44K
Enterprise Value/Ebitda-5.02
Forecast
1Y Price Target
$92.59Price Target Upside170.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)-4.6
Revenue Forecast (FY)N/A
Viking Therapeutics Business Overview & Revenue Model
Company Description
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administere...
How the Company Makes Money
As a clinical-stage biotechnology company, Viking Therapeutics does not primarily generate revenue from commercial product sales because it does not have widely marketed, approved products. Instead, its business model centers on creating sharehold...
Viking Therapeutics Earnings Call Summary
Earnings Call Date:Oct 28, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Feb 10, 2027
Earnings Call Sentiment Positive
The call was strongly positive on clinical and operational progress. Viking reported fully enrolled and on-track subcutaneous Phase III studies, initiation of the oral Phase III program, encouraging efficacy and tolerability results from VK2735 maintenance studies, advancement of VK3019, and a substantially strengthened cash position. The main negative factors were sharply higher operating expenses, a substantially wider net loss, ongoing cash usage of around $100 million per quarter, and uncertainty around future maintenance-study and regulatory outcomes. Highlights significantly outweighed lowlights.Positive Updates
VANQUISH Phase III Program Remains on Track
Both Phase III VANQUISH studies of subcutaneous VK2735—VANQUISH-1 in adults with obesity and VANQUISH-2 in adults with obesity and type 2 diabetes—are fully enrolled and continued to advance according to plan. The studies evaluate weekly doses of 7.5 mg, 12.5 mg and 17.5 mg over 78 weeks, with the first patients expected to enter extension periods in early 2027.
Negative Updates
Quarterly Research and Development Expenses Increased
Third-quarter research and development expenses rose to $166.8 million from $90.0 million in the same period of 2025, an increase of approximately 85%. The increase was primarily attributed to higher clinical-study expenses, manufacturing, stock-based compensation, salaries and benefits, and third-party consultants, partially offset by lower preclinical-study expenses.
Read all updates
Q3-2026 Updates
Positive
Negative
VANQUISH Phase III Program Remains on Track
Both Phase III VANQUISH studies of subcutaneous VK2735—VANQUISH-1 in adults with obesity and VANQUISH-2 in adults with obesity and type 2 diabetes—are fully enrolled and continued to advance according to plan. The studies evaluate weekly doses of 7.5 mg, 12.5 mg and 17.5 mg over 78 weeks, with the first patients expected to enter extension periods in early 2027.
Read all positive updates
Company Guidance
Viking expects the first patients to enter the VANQUISH extension period in early 2027, with the subcutaneous VANQUISH studies assessing once-weekly dosing for 78 weeks; it expects to complete the VK3019 single ascending dose study later this quarter, or by year-end, and plans to initiate a multiple ascending dose study in the first quarter of 2027. The SUNRISE Phase III studies will evaluate oral VK2735 dosed once daily for 68 weeks at 27.5 milligrams, 35 milligrams, 55 milligrams or placebo, with 4-week titration blocks, while Part 2 of the maintenance study will evaluate oral doses ranging from around 17 to 55 with 5 arms, plus 6 subcu arms, 3 every other week and 3 monthly, with results expected in 2027. The company expects a cash usage of average of around $100 million per quarter, with some quarters higher and some lower, SG&A fairly flat in the near term and a pickup later more toward commercialization, which is 2.5 years out from potential launch.Viking Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
55
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -94.00K | -431.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -626.77M | -359.15M | -109.52M | -85.52M | -68.52M | -54.68M |
| Net Income | -627.20M | -359.64M | -109.96M | -85.89M | -68.87M | -54.99M |
Balance Sheet | ||||||
| Total Assets | 977.17M | 715.73M | 908.32M | 368.49M | 168.53M | 210.66M |
| Cash, Cash Equivalents and Short-Term Investments | 959.81M | 705.74M | 902.61M | 362.08M | 155.49M | 202.10M |
| Total Debt | 254.69M | 137.00K | 1.12M | 1.26M | 1.56M | 29.00K |
| Total Liabilities | 388.57M | 76.67M | 28.04M | 20.07M | 23.21M | 8.78M |
| Stockholders Equity | 588.60M | 639.06M | 880.28M | 348.42M | 145.32M | 201.88M |
Cash Flow | ||||||
| Free Cash Flow | -462.63M | -278.69M | -87.79M | -73.38M | -48.40M | -47.59M |
| Operating Cash Flow | -462.63M | -278.69M | -87.79M | -73.38M | -48.40M | -47.59M |
| Investing Cash Flow | 331.75M | 341.39M | -553.37M | -179.09M | 54.75M | 37.96M |
| Financing Cash Flow | 708.32M | 76.44M | 612.46M | 271.38M | 4.16M | 6.88M |
Viking Therapeutics Technical Analysis
Negative
34.17
Price Trends
30.84
Negative
32.78
Negative
32.46
Negative
Market Momentum
-1.86
Positive
40.46
Neutral
26.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VKTX, the sentiment is Negative. The current price of 34.17 is above the 20-day moving average (MA) of 26.94, above the 50-day MA of 30.84, and above the 200-day MA of 32.46, indicating a bearish trend. The MACD of -1.86 indicates Positive momentum. The RSI at 40.46 is Neutral, neither overbought nor oversold. The STOCH value of 26.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VKTX.
Viking Therapeutics Risk Analysis
Viking Therapeutics disclosed 77 risk factors in its most recent earnings report. Viking Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Viking Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $2.52B | -9.67 | -38.33% | ― | -88.87% | -35.06% | |
52 Neutral | $3.22B | -4.70 | -117.35% | ― | ― | -203.77% | |
52 Neutral | $1.53B | -7.09 | -16.91% | ― | ― | 1.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.89B | -5.04 | -57.97% | ― | ― | -19.00% | |
42 Neutral | $3.48B | -0.76 | -15.14% | ― | ― | ― |
* Healthcare Sector Average
VKTX
Viking Therapeutics
26.86
-11.31
-29.63%
NAMS
NewAmsterdam Pharma Company
21.07
-17.65
-45.58%
MLYS
Mineralys Therapeutics, Inc.
21.38
-19.74
-48.01%
GPCR
Structure Therapeutics, Inc. Sponsored ADR
21.48
-10.74
-33.33%
KLRA
Kailera Therapeutics, Inc.
13.42
-12.58
-48.38%
PBLS
Parabilis Medicines, Inc.
28.17
-3.43
-10.85%
Viking Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Viking Therapeutics Raises Capital via Equity and Convertibles
Positive
Sep 28, 2026
On September 23, 2026, Viking Therapeutics entered into an equity underwriting agreement to sell 7,857,143 shares of common stock at $35.00 per share, with underwriters exercising a 30‑day option for an additional 1,178,571 shares on Septemb...
Business Operations and StrategyProduct-Related Announcements
Viking Therapeutics Reports Strong Obesity Drug Maintenance Data
Positive
Sep 22, 2026
On September 22, 2026, Viking Therapeutics reported positive top-line data from a maintenance study of its GLP-1/GIP agonist VK2735 in adults with obesity, showing robust weight loss during a 21-week induction phase and strong maintenance under le...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.